← All trials
NCT04477057
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2019
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2021
- First posted
- Jul 20, 2020
- Last posted
- Jul 20, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Zhengzhou UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- First People's Hospital of HangzhouOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Henan Provincal People's HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.